Thetis Pharmaceuticals to Present at the World Orphan Drug Congress on TP-252, an Investigational Drug for Familial Adenomatous Polyposis

Thetis Pharmaceuticals LLC (“Thetis”), a privately-held biopharmaceutical company, today announced that Frank C. Sciavolino, Ph.D., Chief Scientific Officer, will present an overview of TP-252, the Company’s investigational drug candidate for the treatment of familial adenomatous polyposis (FAP) at the 2016 World Orphan Drug Congress USA. The presentation will take place at the Washington Hilton in Washington, D.C. at 3 pm (EDT) on April 21, 2016.
According to the news:

FAP is a rare genetic cancer predisposition syndrome characterized by the formation of numerous colorectal polyps in late childhood or adolescence. Unless the polyps are removed by surgical procedures, all FAP patients inevitably develop colorectal cancer, usually in middle age. There are no drugs approved by FDA for the treatment of FAP, and disease management currently involves screening, endoscopic surveillance and prophylactic surgery. Colectomy, which is usually performed between the ages of 16 and 20 years, significantly reduces the risk of colorectal cancer, but also imposes a heavy psycho-social burden on this young population.

Click here to view the full press release.